Intellia Thera Form 3	apeutics, Ir	nc.								
May 05, 2016 FORM 3 UNITED STATES SECURITIES AND 2 Washington, D.C								OMB		
		INITIAL S	STATEMENT OF BEN SECURI		OWNERSH	Number: Expires:	3235-0104 January 31, 2005			
		on 17(a) of	t to Section 16(a) of the the Public Utility Holdi 0(h) of the Investment C	ng Compan	y Act of 193:		Estimated a burden hou response 1	•		
(Print or Type F	Responses)									
1. Name and Address of Reporting Person <u>*</u> Novartis Institutes for BioMedical Research, Inc.			2. Date of Event Requiring Statement (Month/Day/Year) 05/05/2016	<sup>g</sup> 3. Issuer Name <b>and</b> Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]						
(Last)	(First)	(Middle)					Amendment, Date Original			
250 MASSACHUSETTS AVENUE				Person(s) to Issuer Filed(Month/Day/Year) (Check all applicable)			1)			
CAMBRID	(Street) GE, MAA	02139		Director Officer (give title belo	Other	r Filing ow)Fo Persor _X_F	orm filed by Mc	ble Line) Reporting		
(City)	(State)	(Zip)	Table I - I	Non-Deriva	tive Securiti	•	ting Person			
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)	of Securities	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		Indirect Benef			
Reminder: Rep owned directly	or indirectly Perso inform requi	ons who res nation cont red to respo	ach class of securities benefic spond to the collection of ained in this form are not ond unless the form displ MB control number.	t s	SEC 1473 (7-02	)				
I	fable II - De	rivative Secu	urities Beneficially Owned (e	.g., puts, calls	, warrants, opt	tions, convert	ible securities	.)		

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

## Edgar Filing: Intellia Therapeutics, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Series A-1 Preferred Stock	(1)	(1)	Common Stock	3,079,001	\$ <u>(1)</u>	D (2)	Â
Series A-2 Preferred Stock	(1)	(1)	Common Stock	1,724,240	\$ <u>(1)</u>	D (2)	Â
Series B Preferred Stock	(1)	(1)	Common Stock	492,640	\$ <u>(1)</u>	D (2)	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Novartis Institutes for BioMedical Research, Inc. 250 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	Â	ÂX	Â	Â	
NOVARTIS AG LICHTSTRASSE 35 BASEL, V8 CH4056	Â	ÂX	Â	Â	
Signatures					
/s/ Scott Brown, Vice President and General Counsel	05	5/05/2016			
**Signature of Reporting Person		Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share is convertible into 0.6465903 of a share of Common Stock at any time at the election of the Reporting Person and will(1) automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.

(2) The shares are held directly by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.